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Abstract 
Background: Newborns are a population in which antibiotic consumption is extremely high. Targeted antibiotic 
therapy should help to reduce antibiotics consumption. The aim of this study was an assessment of antibiotic usage 
in bloodstream infections treatment in the Polish Neonatology Surveillance Network (PNSN) and determining the 
possibility of applying this kind of data in infection control, especially for the evaluation of standard methods of 
microbiological diagnostics.
Methods: Data were collected between 01.01.2009 and 31.12.2013 in five teaching NICUs from the PNSN. The 
duration of treatment in days (DOT) and the defined daily doses (DDD) were used for the assessment of antibiotics 
consumption.
Results: The median DOT for a single case of BSI amounted to 8.0 days; whereas the median consumption expressed 
in DDD was 0.130. In the case of laboratory confirmed BSI, median DOT was 8 days, and consumption—0.120 DDD. 
Median length of therapy was shorter for unconfirmed cases: 7 days, while the consumption of antibiotics was 
higher—0.140 DDD (p < 0.0001). High consumption of glycopeptides expressed in DOTs was observed in studied 
population, taking into account etiology of infection.
Conclusions: Even application of classical methods of microbiological diagnostics significantly reduces the con‑
sumption of antibiotics expressed by DDD. However, the high consumption of glycopeptides indicates the necessity 
of applying rapid diagnostic assays. Nevertheless, the assessment of antibiotic consumption in neonatal units repre‑
sents a methodological challenge and requires the use of different measurement tools.
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Background
Infection control in neonatal intensive care units (NICUs) 
should have high priority, because its incidence is among 
the highest in different patient populations. Bloodstream 
infections (BSI) are the most common clinical form of 
infections in NICUs. The incidence of early-onset BSI 
(diagnosed <3 days after delivery) is 7% in Poland [1] and 
in Norway [2], 6% in the USA [3] and 2.4% in Israel [4].
In contrast, risk of late-onset BSI reaches 14.9/1000 
patient days (pds) worldwide [5]; in the German NeoK-
ISS: 8.3/1000 pds [6] and in Poland—6.7/1000 pds [7]. 
However, in the USA (for infants born at 28 weeks gesta-
tion or earlier)—36% [8], while in Israel, 39% [9].
Numerous studies show that newborns are a popula-
tion in which antibiotic usage is extremely high [10, 11]. 
Those studies were performed mainly in West European 
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countries and in the United States, but there are no such 
reports from Poland or Central Europe.
Assessment of antibiotic usage in neonatal intensive 
care units encounters significant difficulties connected 
with the lack of standardized methods for this specific 
patient population. Defined daily dose (DDD), an inter-
national standard measure used for drug consumption 
assessment, is a technical unit of measurement which 
reflects the average maintenance dose per day for a drug 
used for its main indication in adults [12]. For this rea-
son, this parameter has certain limitations for the analy-
sis in the child population. However, defined daily dose 
was used in some studies, especially for comparative 
purposes in homogenous patient population [13]. Other 
parameters used for antibiotic usage assessment are as 
follows: LOT—the number of days during which at least 
one dose of any antibiotic was received, DOT—the aggre-
gate sum of LOT or PDD—prescribed daily dose or pro-
portion of patients with antibiotic treatment in a specific 
period [14–16].
Antibiotics consumption assessment can have numer-
ous implications. In the area of infection control it can 
serve as a relatively simple indicator for assessing the 
effectiveness of methods of microbiological diagnostics. 
Microbiological diagnostics of blood stream infections in 
hospital practice still remains a challenge.
The aims of this study were:
  • an assessment of antibiotic usage in bloodstream 
infection (BSI) treatment, taking into account etiol-
ogy, in the Polish Neonatal Surveillance Network 
wards using two kinds of parameters, that is DDD 
and DOT,
  • determining the possibility of applying this kind of 
data in infection control, especially for the evalu-
ation of standard methods of microbiological diag-
nostics.
Methods
Data were collected prospectively between 01.01.2009 
and 31.12.2013 in five teaching neonatal intensive care 
units (NICU) that took part in the Polish Neonatology 
Surveillance Network (PNSN). The PNSN is a prospec-
tive national surveillance system for the most relevant 
infections in the group of very low birth weight (birth 
weight  <1500  g, VLBW) infants in Poland. The PNSN 
recorded severe infections, including BSI, observed dur-
ing hospitalization: from admission to discharge, trans-
fer or death. Participation in PNSN was voluntary and 
confidential for wards. Detailed description of data col-
lection system, study wards, epidemiology of early- and 
late-onset BSI and its microbiology have been already 
published elsewhere [1, 7]. The study was approved by 
the Bioethics Committee of Jagiellonian University Medi-
cal College—no. KBET/221/B/2011. All data entered 
into the electronic database and analyzed retrospectively 
during the preparation of this article were previously de-
identified. BSI (both: early- and late-onset) were defined 
according to Gastmeier et  al. [17] with modifications. 
BSI was detected when at least two of the following signs 
were observed:
Temperature >38 or <36.5 °C or temperature instability, 
tachycardia or bradycardia, apnea, prolonged capillary 
refill, metabolic acidosis, hyperglycemia, the other sign of 
bloodstream infections, such as: lethargy; and one of the 
following criteria: C-reactive protein (CRP) >2.0 mg/dL, 
immature/total neutrophil ratio (I/T ratio) >0.2, leuko-
cytes <5000/µL, platelets <10,000/µL.
Early-onset BSI was defined as septicemia diagnosed 
<3 days after delivery.
Laboratory confirmed BSI (LC-BSI) were those cases in 
which positive results of the microbiological testing were 
obtained, that means etiological factor was isolated. All 
blood specimens of at least 1 mL (taken prior to imple-
menting antibiotic treatment) were injected into an aer-
obic blood culture bottle. Isolates were identified by the 
automated identification system (VITEK 2, bioMérieux, 
Poland). In the studied wards, molecular methods for 
identification of etiological factors were not used. BSI 
cases in which samples for microbiological testing were 
not collected or etiological factor was not isolated were 
classified as not confirmed ones.
Antibiotic usage for BSI treatment (until cure) was 
assessed for 767 cases. The analysis of antibiotic use 
included only the cases in which treatment was success-
ful—13 records concerning infants who had died within 
7  days of starting the therapy were excluded from the 
study (all of them were laboratory confirmed).
Two kinds of indicators were used for the description 
of antibiotic usage:
1. DOT, expressed in days—the aggregate (for every 
separate type of antibiotics) sum of number of days 
during which at least one dose of any antibiotic was 
received, and
2. DDD, expressed in grams—the defined daily dose, 
according to the ATC/DDD system of the World 
Health Organization (Anatomical Therapeutic 
Chemical, group “J01”) [12].
Both measures were taken into account in reference to 
one case of infection. Data on the medicine type, dose, 
and the length of therapy were derived from individual 
records in the chart of each individual patient.
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Antibiotic consumption were calculated for all antimi-
crobials used in therapy, and for the following classes: beta-
lactams (ampicillin, cloxacillin, piperacillin, cefotaxime, 
ceftriaxone, ceftazidime, meropenem, imipenem), amino-
glycosides (amikacin, netilmicin, gentamicin), glycopeptides 
(vancomycin), antimycotics (fluconazole, amphotericin 
B) and others (ciprofloxacin, clindamycin, erythromycin, 
clarithromycin, sulfamethoxazole with trimethoprim). 
Etiological factors were assigned to the following groups: 
Gram-negative (Enterobacteriaceae and other rods), Gram-
positive (staphylococci, streptococci), candida. While 
conducting treatment with the application of drugs from 
several groups, used in parallel or consecutively, all of them 
were included into analysis. When, during treatment, posi-
tive microbiological cultures were obtained from different 
samples, or samples taken at different times (within 5 days), 
growth of microorganisms belonging to various groups (e.g. 
Escherichia coli and Candida albicans) was defined as cases 
of changing etiology (group “changing”).
Due to DDD and DOT distribution significantly dif-
ferent from the normality, the statistical analysis based 
on the Kruskal–Wallis test. If the significance had been 
obtained, analysis was suplemented by the post hoc 
Steel–Dwass test, with critical value p = 0.05. All analysis 
were provided with SAS JMP package.
Results
In the study period, records of 2003 VLBW newborns 
and 780 BSI cases (regardless of the date of recognition of 
first BSI symptoms) were filled with all data.
Laboratory confirmed BSI (LC-BSI) constituted 84.9% 
(662) of all recognized cases of BSI.
In the analyzed population of VLBW neonates with 
BSI, in whom the etiological agent was isolated, combina-
tion therapy was used in 67% of cases, while in the group 
without microbiological confirmation, in 74% of cases.
The total duration of antibiotic therapy for 767 cases 
of BSI, which are incorporated into the present analysis, 
amounted to 14,056 DOTs or 381.6 DDDs. The median 
length of antibiotic therapy for a single case of BSI, 
regardless of microbiological confirmation or its lack, 
amounted to 8.0  days; whereas the median consump-
tion expressed in DDD was 0.130. In the case of LC-BSI, 
median DOT was also 8.0 days, and consumption—0.120 
DDD. Median length of therapy was shorter for uncon-
firmed cases: 7.0 days, while the consumption of antibiot-
ics was higher—0.140 DDD (p < 0.0001) (Table 1).
Antibiotic consumption expressed by the DDD index 
was higher in the case of BSI caused by Gram-positive 
cocci than Gram-negative bacilli (0.140 vs. 0.136 DDD, 
Table  2), and the differences concerned 2× higher con-
sumption of aminoglycosides (0.109 vs. 0.056 DDD, 
Table 2; p = 0.0092, Table 3). 
Highest DOT values for beta-lactams concerned fungal 
infections and for the “changing” group, similarly to the 
consumption of antibiotics expressed by DDD.
Median length of therapy for BSI infections caused by 
Gram-positive cocci was longer than the ones caused by 
Gram-negative bacilli (9.0 vs. 7.5 DOT, Table 2), and the dif-
ferences were mainly associated with the employment of gly-
copeptides (8.0 vs. 10.0 DOT, Table 2, p = 0.0004, Table 3).
Detailed data on antibiotic consumption expressed 
by DDD and DOT (values of medians per one infection 
case), taking into account groups of antibiotics, are pre-
sented in Table 2.
The results of statistical analysis regarding the con-
sumption of the individual groups of antibiotics depend-
ing on the etiology of infection are shown in Table 3.
Depending on the applied indicator assessing the con-
sumption of antibiotics in the treatment of BSI: DOT or 
DDD, the percentage share for individual groups of anti-
biotics varied.
Table 1 Values (median) of  DOT and  DDD in  bloodstream infections treatment in  microbiologically confirmed (LC) vs. 
unconfirmed cases (Not-LC)
DOT days of therapy (per one infection case), DDD defined daily dose (per one infection case), IQR interquartile range, N number of BSI cases
Antimicrobial group DOT (days) p value DDD p value
Microbiologically con-
firmed N = 649
Microbiologically 
unconfirmed N = 118
Microbiologically 
confirmed N = 649
Microbiologically 
unconfirmed N = 118
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Aminoglycosides 7.0 (5.0; 9.3) 7.0 (6.0;7.0) 0.5265 0.101 (0.050; 0.171) 0.095 (0.045; 0.179) <0.0001
Antimycotic 12.5 (9.0;16.0) 10.0 (7.8;14.3) 0.210 (0.132; 0.040) 0.198 (0.073; 0.463)
Beta‑lactams 8.0 (5.0;11.0) 7.0 (6.8;8.8) 0.254 (0.136; 0.438) 0.300 (0.210; 0.420)
Glycopeptides 10.0 (8.0;11.0) 9.0 (7.0;11.0) 0.120 (0.080; 0.168) 0.120 (0.083; 0.146)
Other 9.0 (6.0;14.8) 8.0 (5.0;15.5) 0.210 (0.105; 0.530) 0.098 (0.060; 0.410)
Total 8.0 (5.0; 16.0) 7.0 (5.0; 15.5) 0.120 (0.050; 0.530) 0.143 (0.045; 0.463)
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In treatment of BSI as a whole, according to the DOT 
index, glycopeptides were used the longest: 42.1%, and, 
after taking into account the etiology of infection, it 
was the predominant group also in infections caused by 
Gram-positive cocci: 51%, in the event of changes in the 
etiological agent: 40.6%. In treatment of microbiologi-
cally unconfirmed BSI, glycopeptides were used in 33.8% 
DOT (Fig. 1).
The largest share in total consumption of antibiotics in 
all analyzed cases of BSI expressed by DDD was repre-
sented by beta-lactams: 32.6%, especially with microbio-
logically unconfirmed BSI: 53.2% (Fig. 2).
In the event when antibiotic consumption was evalu-
ated by DDD, antifungal medication constituted almost 
one-fourth of the applied drugs, and when the unit of 
measurement was DOT—13.3% (Figs. 1, 2).
Discussion
BSI represent a critical complication associated with hos-
pitalization of very low birth weight (VLBW) infants, 
contributing to longer stay, and different long-term 
adverse outcomes. This phenomenon is well-understood 
and described [3, 7, 18–21], contrary to the subject under 
discussion, in which, unfortunately, data concerning anti-
biotic consumption are sparse and incomplete.
The proportion of microbiologically confirmed cases 
of BSI observed in the present study indicates similar-
ity, but not identicalness, with other national programs. 
In the analysis of differences, attention should be paid 
to the applied definition of infections and different sig-
nificance of microbiological findings for various types of 
surveillance. In American NHSN, in which to confirm 
LC-BSI, it was necessary to obtain at least 2 identical 
blood cultures, clinical sepsis was observed in 6.7–12.7% 
of infections [22], i.e. twice less frequently than in this 
study—significantly less restrictive in evaluating microbi-
ological results. It unfortunately, indicates too rare appli-
cation of the capabilities of contemporary microbiology 
in everyday clinical practice of the studied NICUs. This 
is confirmed by the results of a Cypriot study, in which 
LC-BSI constituted 96% of all BSIs [23]. Another matter 
is the debated problem of legitimacy of repeated blood 
drawing for cultures from VLBW newborns. Currently, it 
is more and more frequently assumed that, in this patient 
population, it is more justifiable to draw a single full-vol-
ume sample than to take two or more—even in the event 
of a result revealing typical skin contaminants, i.e. coagu-
lase-negative staphylococci [24]. This is confirmed by the 
definitions adopted in the Netherlands [25], in NICHD 
Vermont Oxford Network [3] and the ones employed in 
the German national program called Neo-KISS [17].
The obtained data show that the use of diagnostics, 
even based on the standard, basic level, meaning cul-
ture, is a proceeding effectively affecting the consump-
tion of antibiotics, and therefore, the costs of therapy, i.e. 
they reduce the consumption of antibiotics expressed by 
DDD.
The indicator most commonly used to assess the con-
sumption of drugs, including antibiotics, is defined daily 
dose. This recognized international standard applicable 
in measuring the consumption of antibiotics is based 
on the average dose for the treatment of adults. For this 
reason, it is an indicator which, in relation to children, 
should be used with caution and one should take into 
account its limitations [26, 27].
Table 2 Values (median) of  DOT and  DDD in  bloodstream 
infections treatment according to etiological factors
Changing—when, during treatment, positive microbiological cultures were 
obtained from different samples, or samples taken at different times (within 
5 days), growth of microorganisms belonging to various groups (e.g. Escherichia 
coli and Candida albicans) was defined as cases of changing etiology (group 
“changing”)
DOT days of therapy (per one case), DDD defined daily dose (per one case), IQR 
interquartile range, N number of cases
Etiology DOT (days) DDD
Median (IQR) Median (IQR)
Gram+ N = 452
 Aminoglycosides 7.0 (5.0; 9.0) 0.109 (0.560; 0.180)
 Antimycotics 12.0 (9.3; 16.0) 0.195 (0.131; 0.341)
 Beta‑lactams 7.0 (5.0; 10.0) 0.252 (0.180; 0.420)
 Glycopeptides 10.0 (8.0; 11.0) 0.128 (0.088; 0.168)
 Other 9.0 (5.0; 15.0) 0.211 (0.096; 0.452)
 Total 9.0 (5.0; 15.0) 0.140 (0.056; 0.453)
Gram− N = 103
 Aminoglycosides 6.0 (4.3; 8.0) 0.056 (0.036; 0.137)
 Antimycotics 12.0 (8.2; 17.0) 0.228 (0.131; 0.360)
 Beta‑lactams 8.0 (4.0; 11.0) 0.244 (0.096; 0.448)
 Glycopeptides 8.0 (4.0; 9.0) 0.098 (0.039; 0.149)
 Other 8.5 (5.3; 10.8) 0.229 (0.099; 0.608)
 Total 7.5 (4.0; 17.0) 0.136 (0.036; 0.447)
Changing N = 76
 Aminoglycosides 7.0 (5.0; 10.0) 0.105 (0.061; 0.180)
 Antimycotics 12.0 (10.0; 16.0) 0.250 (0.158; 0.735)
 Beta‑lactams 7.0 (6.5; 11.0) 0.281 (0.169; 0.495)
 Glycopeptides 10.0 (7.0; 11.0) 0.085 (0.056; 0.167)
 Other 9.0 (6.0; 14.5) 0.187 (0.120; 2.580)
 Total 9.0 (5.0; 16.0) 0.149 (0.056; 2.580)
Candida N = 18
 Aminoglycosides 8.5 (4.8; 12.8) 0.140 (0.070; 0.210)
 Antimycotics 10.5 (9.0; 15.8) 0.225 (0.092; 0.353)
 Beta‑lactams 12.0 (9.0; 19.5) 450 (192.9; 2175)
 Glycopeptides 10.0 (7.3; 10.8) 0.087 (0.063; 0.161)
 Other 13.5 (10.0; 17.0) 3.276 (0.153; 6.400)
 Total 10.0 (4.8; 19.5) 0.164 (0.063; 6.400)
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Table 3 Statistical significance of antibiotic consumption expressed in DOT and DDD in bloodstream infections treatment 
according to etiological factor
Candida Gram– Gram+ Changing
DOT aminoglycosides (H = 6.5939, df = 4; p = 0. 590)
Not LC 0.7346 0.4524 0.9929 0.2733
Candida na 0.6917 0.9235 0.9962
Gram– na 0.4358 0.2780
Gram+ na 0.8323
Total DDD aminoglycosides (H = 31.7944, df = 4; p < 0.0137)
Not LC 0.7980 0.3370 0.5284 0.9576
Candida na 0.3438 0.9582 0.9757
Gram– na 0.0092 0.3480
Gram+ na 1.0000
DOT antifungals (H = 2.5563, df = 4; p = 0.6346)
Not LC 0.9978 0.9978 0.8403 0.7241
Candida na 0.9995 0.9155 0.8539
Gram– na 0.9885 0.8474
Gram+ na 0.9753
Total DDD antifungals (H = 16.5505, df = 4; p = 0.4042)
Not LC 0.1485 0.7166 0.9926 0.7086
Candida na 0.3429 0.4524 0.9454
Gram– na 0.2909 0.9236
Gram+ na 0.1509
DOT beta-lactams (H = 15.0687, df = 4; p = 0.0046)
Not LC 0.0286 0.8176 0.7340 0.0039
Candida na 0.2451 0.1935 0.3721
Gram– na 0.9978 0.2494
Gram+ na 0.1390
Total DDD beta-lactams (H = 11.2708, df = 4; p = 0.1930)
Not LC 0.6238 0.3438 0.2861 0.3044
Candida na 0.9999 0.9852 1.0000
Gram– na 0.6380 1.0000
Gram+ na 0.7880
DOT glycopeptides (H = 19.0396, df = 4; p = 0.0008)
Not LC 0.9986 0.0481 0.4925 0.9997
Candida na 0.4196 0.9989 0.9992
Gram– na 0.0004 0.1049
Gram+ na 0.6125
Total DDD glycopeptides (H = 0.4767, df = 4; p = 0.0010)
Not LC 0.8227 0.5865 0.4612 0.5951
Candida na 1.0000 0.4731 0.9998
Gram– na 0.0498 0.9802
Gram+ na 0.0157
DOT other (H = 2.2959, df = 4; p = 0.6815)
Not LC 0.6828 0.9978 0.9220 0.9922
Candida na 0.7617 0.8871 0.9772
Gram– na 0.9735 0.9984
Gram+ na 0.9999
Total DDD other (H = 3.8955, df = 4; p = 0.3787)
Not LC 0.9707 0.9538 0.8169 0.9981
Candida na 0.9986 0.4667 0.5815
Gram– na 0.8990 0.9884
Gram+ na 0.9910
p values for each pair of etiological factor groups are given in the table cells
Changing—when, during treatment, positive microbiological cultures were obtained from different samples, or samples taken at different times (within 5 days), 
growth of microorganisms belonging to various groups (e.g. Escherichia coli and Candida albicans) was defined as cases of changing etiology (group “changing”)
DOT days of therapy, DDD defined daily dose, IQR interquartile range, na not applicable, Not LC not laboratory confirmed
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Howether, both measures: DDD and the length of ther-
apy were used by different authors with the application of 
various denominators—the number of admissions, num-
ber of person days or with respect to the treatment of a 
single patient [13, 15].
To evaluate the consumption of antibiotics in pedi-
atric wards, particularly neonatal units, Gerber et  al. 
employed DOT [15]. Depending on the type of neona-
tal unit, they found the length of treatment to be in the 
range from 5.7 in medical NICUs to 34.3 DOT in surgical 
NICUs. Median DOT in this study was about forty per-
cent higher than in the medical NICUs in the study by 
Gerber; however, due to distinct populations and differ-
ent degrees of detail, it is difficult to explicitly compare 
these values. Studies concerning antibiotic consumption 
in the neonatal population are not numerous, but what 
is more important: the published papers present a differ-
entiated approach to the subject and are carried out with 
the use of diverse methodology and for various needs [5, 
11, 13, 26, 28].
However, the main objective of this study was the anal-
ysis of the evaluation of antibiotic consumption in the 
treatment of one form of infection in a narrow and spe-
cific patient population, giving special consideration to 
the possibility of its use in the evaluation of the effective-
ness and accuracy of microbiological diagnostics as an 
element of surveillance of infections in NICU.
And so, in NICUs covered by the study, significantly 
lower consumption of antibiotics expressed by DDD was 
observed in the case of LC-BSI treatment, compared to 
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those in which the etiological agent was not isolated. On 
this basis, it can be concluded that the microbiological 
diagnosis of BSI in newborns treated in NICU was con-
ducted properly and the results of microbiological tests 
were used in targeted therapy, what made it possible to 
obtain a reduction in the consumption of antimicrobial 
drugs and, consequently, the cost of treatment. In Pol-
ish NICUs, costs of medication account for nearly one-
fifth of the total cost of treatment, the amount of which 
is inversely proportional to a child’s birth weight and 
directly proportional to the length of hospitalization [20].
A different situation was observed in the population of 
the PNSN neonates, who developed necrotising entero-
colitis, wherein the length of therapy and consumption 
rates were not affected by the isolation of the potential 
etiological agent [29]. But with NEC, difficulties present 
themselves as regards obtaining material for microbio-
logical examination, which would enable the isolation 
of the etiological agent. The quoted results concerning 
antibiotic consumption in NEC cases and the ones dem-
onstrated in the present study regarding BSI illustrate 
the possibilities of how analyses in this respect could be 
utilized in infection control and, in particular, in evalu-
ation of adequacy and effectiveness of microbiological 
diagnostics.
On the other hand, no significant differences in DOT 
values in cases of LC-BSI and microbiologically uncon-
firmed BSI were observed. This is contradictory to the 
current approach to modern antimicrobial stewardship: 
in newborn population, with suspected BSI, it is recom-
mended to terminate antibiotic treatment after 48 h since 
the identification of symptoms, if the infection was not 
confirmed microbiologically. Even traditional diagnostics 
based on the culture method ensures obtaining a positive 
result (information on microbial etiology of infection) 
within 48 h [30, 31].
For antimicrobial stewardship to efficiently and effec-
tively influence the reduction of antibiotic consumption, 
but not to decrease patient safety, in neonatal units, a 
principle of daily detailed review of the situation of neo-
nates treated with antibiotics should be introduced, so as 
to minimize the intake of antibiotics in children, whose 
blood cultures and other clinical specimens tested nega-
tive and symptoms of infection are no longer observed or 
infectious origin of the disease was excluded. The lack of 
significant differences in DOT values of laboratory con-
firmed vs. not-confirmed BSI cases would point to the 
fact that these recommendations are not applied in the 
PNSN wards.
It should also be noted that rapid diagnostic molecu-
lar methods (which enable rapid assessment of the need 
to implement or discontinue therapy with vancomy-
cin) could be implemented to decrease glycopeptides 
consumption, because glycopeptides are not easy to use 
in neonates [32, 33]. For it has been observed that the use 
of glycopeptides in the case of BSI caused by Enterobac-
teriaceae was lower by only approx. 20% in comparison 
with BSI caused by Gram-positive cocci. Generally, in 
our study, in treatment of BSI as a whole glycopeptides 
were used the longest. Similar situation was reported in 
study of Sameer et al. [34].
As for aminoglycosides, only the use of the DDD indi-
cator permitted the demonstration of their significantly 
increased consumption in BSI caused by Gram-positive 
cocci (109 DDD), in comparison with BSI that were 
caused by Gram-negative bacilli (56.1 DDD).
Also noteworthy is the fact that there is a large share 
of antifungal drugs in the treatment of the analyzed 
cases of BSI, 25% of the entire consumption expressed 
by DDD (13.3% DOT), with simultaneous, lower than 
anticipated, participation of yeast-like fungi isolated in 
microbiological testing [35, 36]. This coincides with the 
trends observed in other studies. According to Fridkin, 
the application of fluconazole in infection prophylaxis 
contributed to this fact, which is also confirmed by other 
authors [6]. Thus, the high level of antimycotic medica-
tion consumption in PNSN wards fulfilled the task of 
reducing the incidence of fungal infections.
Antibiotic consumption assessment using at least two 
different measures, as presented in our study, can be a 
useful tool in antibiotic stewardship [27]. In present-
ing case, the results of the analysis indicate the need of 
implementing more sensitive and faster methods of 
microbiological diagnostics (PCR and/or MALDI-TOF) 
as a first step of reducing antibiotics consumption due to 
faster identification of etiological factor of infection. PCR 
increases the sensitivity of diagnostics test and shortens 
the time of identification of microorganisms without cul-
ture. MALDI-TOF improves the specificity and shortens 
the time of identification after receiving microorganism 
grow in culture method [37, 38]. These diagnostics tech-
niques are still very rarely used in Polish hospital. They 
are considered as expensive procedures by hospitals’ 
management, because complex cost-effectiveness analy-
sis in the field of infection control, taking into account 
at least the cost of prolonged hospital stay, are not per-
formed. In the study patient population occurrence of 
BSI significantly increases length of stay in NICU, by 
approximately 20 days [21].
Conclusions
Analysis of antibiotic consumption is an essential 
component of infection control, especially for NICU 
patients—for effective planning and reliable evaluation of 
interrelationships between individual elements of control 
programs.
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Application of classical methods of microbiological 
diagnostics based on blood cultures significantly reduces 
the consumption of antibiotics expressed by DDD.
High consumption of glycopeptides marked by DOT 
indicates the necessity of applying rapid diagnostic 
assays.
Nevertheless, the assessment of antibiotic consumption 
in neonatal units represents a methodological challenge 
and requires the use of different measurement tools.
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